Altamira Therapeutics Ltd
Company Profile
Business description
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy, viral infections, and inner ear disorders. Its product Bentrio, is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows for the delivery of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
Contact
2 Church Street
Clarendon House
HamiltonHM11
BMUT: +1 441 295-5950
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
ASX listed gold miner under pressure due to lower production
stocks
3 ASX opportunities after earnings season
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,822.00 | 27.20 | 0.31% |
| CAC 40 | 7,935.97 | 24.44 | 0.31% |
| DAX 40 | 23,564.01 | 116.72 | 0.50% |
| Dow JONES (US) | 46,946.41 | 387.94 | 0.83% |
| FTSE 100 | 10,317.69 | 56.54 | 0.55% |
| HKSE | 25,834.02 | 368.42 | 1.45% |
| NASDAQ | 22,374.18 | 268.82 | 1.22% |
| Nikkei 225 | 53,751.15 | 68.46 | -0.13% |
| NZX 50 Index | 13,164.24 | 0.34 | -0.00% |
| S&P 500 | 6,699.38 | 67.19 | 1.01% |
| S&P/ASX 200 | 8,616.40 | 40.80 | 0.48% |
| SSE Composite Index | 4,084.79 | 10.66 | -0.26% |